The reduction in price target by B of A Securities suggests a tempered outlook for ACADIA Pharmaceuticals, potentially leading to a negative short-term impact on its stock price. The maintenance of a Neutral rating indicates that the analyst sees limited upside or downside potential from the current price level, but the lowering of the price target could influence market perception negatively.